Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-01-25

AUTHORS

Hyun-Jae Kang, Matthew T. Roe

ABSTRACT

The clinical trials that failed to demonstrate significant efficacy may not result in development of new therapy but contribute to better understanding of antithrombotic therapy for ischemic heart disease. Negative trials provide important messages about how to interpret and understand the results of clinical trials and apply these results to clinical practices. Although every aspect of clinical trials may influence the outcomes of trials and interpretation of their results, selection of study subjects, endpoints, and measuring risk/benefit are crucial to success of clinical trial. We will review the recent key negative trials on antithrombotic therapy for ischemic heart disease and discuss about their results and implications. The challenge in the future for the development of antithrombotic therapies is to leverage these “lessons learned” from negative clinical trials to improve the design, conduct, and interpretation of future randomized clinical trials. More... »

PAGES

112-125

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12265-013-9532-6

DOI

http://dx.doi.org/10.1007/s12265-013-9532-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052606940

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24464592


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Evidence-Based Medicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrinolytic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Ischemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Glycoprotein GPIIb-IIIa Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Duke Clinical Research Institute, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Clinical Research Institute, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kang", 
        "givenName": "Hyun-Jae", 
        "id": "sg:person.01254550333.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254550333.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke Clinical Research Institute, Durham, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Clinical Research Institute, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roe", 
        "givenName": "Matthew T.", 
        "id": "sg:person.0674336554.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674336554.45"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2014-01-25", 
    "datePublishedReg": "2014-01-25", 
    "description": "The clinical trials that failed to demonstrate significant efficacy may not result in development of new therapy but contribute to better understanding of antithrombotic therapy for ischemic heart disease. Negative trials provide important messages about how to interpret and understand the results of clinical trials and apply these results to clinical practices. Although every aspect of clinical trials may influence the outcomes of trials and interpretation of their results, selection of study subjects, endpoints, and measuring risk/benefit are crucial to success of clinical trial. We will review the recent key negative trials on antithrombotic therapy for ischemic heart disease and discuss about their results and implications. The challenge in the future for the development of antithrombotic therapies is to leverage these \u201clessons learned\u201d from negative clinical trials to improve the design, conduct, and interpretation of future randomized clinical trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12265-013-9532-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1039754", 
        "issn": [
          "1937-5387", 
          "1937-5395"
        ], 
        "name": "Journal of Cardiovascular Translational Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "ischemic heart disease", 
      "antithrombotic therapy", 
      "clinical trials", 
      "negative clinical trials", 
      "heart disease", 
      "negative trials", 
      "risk/benefit", 
      "outcomes of trials", 
      "significant efficacy", 
      "new therapies", 
      "study subjects", 
      "clinical practice", 
      "therapy", 
      "trials", 
      "disease", 
      "endpoint", 
      "efficacy", 
      "outcomes", 
      "subjects", 
      "better understanding", 
      "important message", 
      "development", 
      "results", 
      "benefits", 
      "practice", 
      "success", 
      "implications", 
      "lessons", 
      "challenges", 
      "understanding", 
      "aspects", 
      "conduct", 
      "interpretation", 
      "future", 
      "selection", 
      "messages", 
      "design", 
      "recent key negative trials", 
      "key negative trials"
    ], 
    "name": "Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease", 
    "pagination": "112-125", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052606940"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12265-013-9532-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24464592"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12265-013-9532-6", 
      "https://app.dimensions.ai/details/publication/pub.1052606940"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_632.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12265-013-9532-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12265-013-9532-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12265-013-9532-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12265-013-9532-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12265-013-9532-6'


 

This table displays all metadata directly associated to this object as RDF triples.

156 TRIPLES      21 PREDICATES      77 URIs      69 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12265-013-9532-6 schema:about N029a707ae1474fe390db016a26a2a566
2 N34234257fa8848e48922eedb666ba12f
3 N5329d745fd4147afa9f7819692fefcff
4 N607782fc05784e12abef91ed352660c9
5 N9d2cbdd086c24a429330e74fbb36239f
6 Naf9d2dd3d19c4268b47295a403c24629
7 Nc3eff6d07bf942eb954548286a3b5efd
8 Nddb4c21c6c354d74ab2a073a172d844a
9 Ne0a5b5d32bd94e6bbb64d5219371157d
10 Ne76f2adf7da646979575f62e48124e0a
11 Nf21c00e51e0549bfbb00e2cce403abde
12 Nf32f12ef339a4954ada082f313a16739
13 anzsrc-for:11
14 anzsrc-for:1102
15 schema:author N621cfb8c449e4b2ab838183db7647145
16 schema:datePublished 2014-01-25
17 schema:datePublishedReg 2014-01-25
18 schema:description The clinical trials that failed to demonstrate significant efficacy may not result in development of new therapy but contribute to better understanding of antithrombotic therapy for ischemic heart disease. Negative trials provide important messages about how to interpret and understand the results of clinical trials and apply these results to clinical practices. Although every aspect of clinical trials may influence the outcomes of trials and interpretation of their results, selection of study subjects, endpoints, and measuring risk/benefit are crucial to success of clinical trial. We will review the recent key negative trials on antithrombotic therapy for ischemic heart disease and discuss about their results and implications. The challenge in the future for the development of antithrombotic therapies is to leverage these “lessons learned” from negative clinical trials to improve the design, conduct, and interpretation of future randomized clinical trials.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf Nd18c617ced504368a1da76873fcb04d2
23 Neff86b725922406a922d60c2f64deec2
24 sg:journal.1039754
25 schema:keywords antithrombotic therapy
26 aspects
27 benefits
28 better understanding
29 challenges
30 clinical practice
31 clinical trials
32 conduct
33 design
34 development
35 disease
36 efficacy
37 endpoint
38 future
39 heart disease
40 implications
41 important message
42 interpretation
43 ischemic heart disease
44 key negative trials
45 lessons
46 messages
47 negative clinical trials
48 negative trials
49 new therapies
50 outcomes
51 outcomes of trials
52 practice
53 recent key negative trials
54 results
55 risk/benefit
56 selection
57 significant efficacy
58 study subjects
59 subjects
60 success
61 therapy
62 trials
63 understanding
64 schema:name Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease
65 schema:pagination 112-125
66 schema:productId N30404169ecf240cc9a3217e59d980043
67 N5de55f2afd15482b82ac5330b21a3175
68 N7f20abc1ddd944489b720d10b127575b
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052606940
70 https://doi.org/10.1007/s12265-013-9532-6
71 schema:sdDatePublished 2022-01-01T18:34
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N7a08208c5db14a189519a7f37e48c037
74 schema:url https://doi.org/10.1007/s12265-013-9532-6
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N029a707ae1474fe390db016a26a2a566 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Treatment Outcome
80 rdf:type schema:DefinedTerm
81 N30404169ecf240cc9a3217e59d980043 schema:name dimensions_id
82 schema:value pub.1052606940
83 rdf:type schema:PropertyValue
84 N34234257fa8848e48922eedb666ba12f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Myocardial Ischemia
86 rdf:type schema:DefinedTerm
87 N5329d745fd4147afa9f7819692fefcff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Clinical Trials as Topic
89 rdf:type schema:DefinedTerm
90 N5de55f2afd15482b82ac5330b21a3175 schema:name pubmed_id
91 schema:value 24464592
92 rdf:type schema:PropertyValue
93 N607782fc05784e12abef91ed352660c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Platelet Glycoprotein GPIIb-IIIa Complex
95 rdf:type schema:DefinedTerm
96 N621cfb8c449e4b2ab838183db7647145 rdf:first sg:person.01254550333.69
97 rdf:rest N67c285b6987a4034b30e64b0a872b661
98 N67c285b6987a4034b30e64b0a872b661 rdf:first sg:person.0674336554.45
99 rdf:rest rdf:nil
100 N7a08208c5db14a189519a7f37e48c037 schema:name Springer Nature - SN SciGraph project
101 rdf:type schema:Organization
102 N7f20abc1ddd944489b720d10b127575b schema:name doi
103 schema:value 10.1007/s12265-013-9532-6
104 rdf:type schema:PropertyValue
105 N9d2cbdd086c24a429330e74fbb36239f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Humans
107 rdf:type schema:DefinedTerm
108 Naf9d2dd3d19c4268b47295a403c24629 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Risk Assessment
110 rdf:type schema:DefinedTerm
111 Nc3eff6d07bf942eb954548286a3b5efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Anticoagulants
113 rdf:type schema:DefinedTerm
114 Nd18c617ced504368a1da76873fcb04d2 schema:issueNumber 1
115 rdf:type schema:PublicationIssue
116 Nddb4c21c6c354d74ab2a073a172d844a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Fibrinolytic Agents
118 rdf:type schema:DefinedTerm
119 Ne0a5b5d32bd94e6bbb64d5219371157d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Evidence-Based Medicine
121 rdf:type schema:DefinedTerm
122 Ne76f2adf7da646979575f62e48124e0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Risk Factors
124 rdf:type schema:DefinedTerm
125 Neff86b725922406a922d60c2f64deec2 schema:volumeNumber 7
126 rdf:type schema:PublicationVolume
127 Nf21c00e51e0549bfbb00e2cce403abde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Hemorrhage
129 rdf:type schema:DefinedTerm
130 Nf32f12ef339a4954ada082f313a16739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Platelet Aggregation Inhibitors
132 rdf:type schema:DefinedTerm
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
137 schema:name Cardiorespiratory Medicine and Haematology
138 rdf:type schema:DefinedTerm
139 sg:journal.1039754 schema:issn 1937-5387
140 1937-5395
141 schema:name Journal of Cardiovascular Translational Research
142 schema:publisher Springer Nature
143 rdf:type schema:Periodical
144 sg:person.01254550333.69 schema:affiliation grid-institutes:grid.26009.3d
145 schema:familyName Kang
146 schema:givenName Hyun-Jae
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254550333.69
148 rdf:type schema:Person
149 sg:person.0674336554.45 schema:affiliation grid-institutes:grid.26009.3d
150 schema:familyName Roe
151 schema:givenName Matthew T.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674336554.45
153 rdf:type schema:Person
154 grid-institutes:grid.26009.3d schema:alternateName Duke Clinical Research Institute, Durham, NC, USA
155 schema:name Duke Clinical Research Institute, Durham, NC, USA
156 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...